Vietnam ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis

Vietnam Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Executive Analysis

The Vietnam Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market size is at around $148 Mn in 2022 and is projected to reach $268 Mn in 2030, exhibiting a CAGR of 7.73% during the forecast period. From $16.1 Bn in 2017 to $20 Bn in 2022, healthcare expenditure in Vietnam increased steadily. It is expected to reach $23.3 Bn in 2025 and $33.8 Bn in 2030. The projections are based on a compound annual growth rate (CAGR) of 7.6%, according to a Vietnam study. The government's initiatives to make healthcare more accessible and affordable, the aging population of the nation, increased awareness of healthcare requirements, and rising incomes all contribute to this development. According to the company's October-November survey, pharmaceutical companies reported greater year-over-year revenues and profits in the first nine months of the year in 85.7% and 78.6% of cases, respectively.

ADHD is a mental disorder that typically first appears in infancy and is characterized by hyperactivity, impulsivity, and inattention.  In Vietnam, a study revealed that the prevalence of ADHD was 7.7% and doubled among adolescents residing in urban areas compared to those in rural ones. Patients with ADHD and their families also experience unavoidable burdens, such as poor financial support for care and schooling along with mounting mental stress. The biological factors that cause infants to develop ADHD syndromes are still largely unknown. There are many highly heritable, multifactorial risk factors that are influenced by gene-environment interactions rather than a singular risk factor that causes this disorder. Furthermore, prenatal and perinatal factors, such as adverse childhood experiences, maternal pregnancy risk exposures, and complications, have been recognized as risks, but defined causes have not yet been widely established.

Children's health in relation to ADHD needs to be given more thought in light of Vietnam's growing urbanization, which could ultimately raise the risk of ADHD syndrome due to gene-environmental interactions. Vietnamese children, like those in other developing nations, are receiving more attention and funding for their education and health treatment than their ancestors. However, there hasn't been enough evidence of mental health issues or demands—in particular, the prevalence of ADHD and related factors—to propose suitable health managements that are thought to be workable for families and primary schools.

Medication, behavior-focused therapies, health counseling, and instruction are common treatments for ADHD in children of all ages in Vietnam Many of the symptoms of ADHD can be reduced with these therapies. Although psychotropic drugs (such as methylphenidate, a central nervous system stimulant) are successful in reducing the symptoms of ADHD, pharmacotherapy is rarely enough to address the wide range of functional impairments that young people with this disorder experience. Medication must be combined with psychosocial and educational interventions because they enhance social, academic, and behavioral performance.

Market Dynamics

Market Growth Drivers

As a result of increasing urbanization in Vietnam, ADHD incidence among school-going children is on the rise. Healthcare expenditure is anticipated to increase as Vietnam's economy expands. This will make healthcare services more widely available, including choices for treating ADHD. The Vietnamese government has been making investments in the infrastructure of the healthcare system, which includes modernizing and expanding healthcare centers. This will make ADHD easier to diagnose and manage. As more businesses enter the market and create novel medications for the treatment of ADHD, the Vietnam ADHD therapeutics market will expand.

Market Restraints

Many Vietnamese families might not be able to handle the cost of medications and therapy due to the high cost of ADHD treatment. Even though Vietnam's pharmaceutical business is expanding, some ADHD medications might not be widely accessible. This can make it challenging for those who have ADHD to find efficient treatment choices.

Competitive Landscape

Key Players

• DHG Pharma (VNM)
• Traphaco (VNM)
• Pymepharco (VNM)
• ImexPharm Pharmaceutical (VNM)
• Binh Dinh Pharmaceutical (VNM)
• Eli Lily
• Pizer
• Johnson & Johnson
• Lupin
• Shire
• Mallinckrodt
• Prude Pharma
• NEOS Therapeutics

Healthcare Policies and Regulatory Landscape

The primary regulatory body in charge of regulating drugs, cosmetics, and medical devices in Vietnam is the Drug Administration of Vietnam (DAV). It is a division of the Ministry of Health, and its main responsibility is to guarantee the security, efficacy, and high caliber of all goods manufactured for use by people. All drugs distributed in Vietnam, including prescription, over-the-counter, and traditional medicines, must be licensed and registered with the DAV. Clinical trials are required to show a drug's safety and effectiveness before it can be authorized for use in Vietnam. Clinical trials must be approved by the DAV, which also makes sure they are carried out in accordance with international norms. Once a drug is on the market, the DAV is in charge of keeping track of its safety. This includes keeping an eye on negative drug reactions, carrying out post-marketing surveillance, and taking the necessary regulatory action in the event that safety issues emerge. To make sure that drug distributors and manufacturers are adhering to regulatory requirements, the DAV is in charge of performing checks. Furthermore, it has the power to impose penalties on those who break the law.